Skip to Main Content

NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a unique, off-the-shelf therapy made from a special type of T cell that induced complete remissions in patients with advanced and aggressive B cell lymphomas. But an update reported Saturday showed patients starting to relapse, which may raise questions about the so-called gamma-delta T cell therapy’s durability.

In an early-stage study, two of six patients, or 33%, have maintained complete remissions for at least six months — a closely watched marker of durability. The patients received single infusions of Adicet’s therapy, called ADI-001, containing 100 million or 300 million cells.


Last June, the complete remission rate for these same patients was 80%, although with short follow-up.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.